Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

News > Health News

Audio By Carbonatix

4:05 PM on Thursday, March 12

The Associated Press

SAN DIEGO--(BUSINESS WIRE)--Mar 12, 2026--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time.

A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260311845284/en/

CONTACT: Investor Contact:

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

[email protected] Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH MENTAL HEALTH CLINICAL TRIALS

SOURCE: Acadia Pharmaceuticals Inc.